PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells

Molecular Oncology

Volumn 8, Issue 5, 2014, Pages 968-981

  Plantamura, Ilaria ^a   Casalini, Patrizia ^a   Dugnani, Erica ^a   Sasso, Marianna ^a   D'Ippolito, Elvira ^a   Tortoreto, Monica ^a   Cacciatore, Matilde ^b   Guarnotta, Carla ^b   Ghirelli, Cristina ^a   Barajon, Isabella ^c   Bianchi, Francesca ^a   Triulzi, Tiziana ^a   Agresti, Roberto ^a   Balsari, Andrea ^c   Campiglio, Manuela ^a   Tripodo, Claudio ^b   Iorio, Marilena V ^a   Tagliabue, Elda ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

FGFR; PDGFR; TNBC; Vasculogenic mimicry

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P53; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOTHELIUM CELL; ERYTHROCYTE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MCF 7 CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BREAST; CYTOLOGY; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE; VASCULARIZATION; ANGIOGENESIS; BREAST CANCER CELL LINE; CANCER INHIBITION; CONFOCAL MICROSCOPY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG TARGETING; GENE SILENCING; HUMAN CELL; IMMUNOFLUORESCENCE; TUMOR XENOGRAFT; VASCULAR TUMOR;

ANIMALS; BREAST; CELL DIFFERENTIATION; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84903547577     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.03.015     Document Type: Article

References (31)

1. Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform. J. Biol. Chem. 2009, 284:6227-6240.
2. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., Perou C.M., Nielsen T.O. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14:1368-1376.
3. Dawood S., Broglio K., Kau S.W., Green M.C., Giordano S.H., Meric-Bernstam F., Buchholz T.A., Albarracin C., Yang W.T., Hennessy B.T., Hortobagyi G.N., Gonzalez-Angulo A.M. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J. Clin. Oncol. 2009, 27:220-226.
4. Dey J.H., Bianchi F., Voshol J., Bonenfant D., Oakeley E.J., Hynes N.E. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 2010, 70:4151-4162.
5. Di Leva G., Gasparini G., Piovan C., Ngankeu A., Garofalo M., Taccioli C., Iorio M.V., Li M., Volinia S., Alder H., Nakamura T., Nuovo G., Liu Y., Nephew K.P., Croce C.M. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J. Natl. Cancer I 2010, 102:706-721.
6. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009, 15:232-239.
7. Ellis I.O., Elston C.W. Histologic grade. Breast Pathology 2006, 225-233. Elsevier, Philadelphia, PA. F.P. O'Malley, S.E. Pinder (Eds.).
8. Farmer P., Bonnefoi H., Becette V., Tubiana-Hulin M., Fumoleau P., Larsimont D., MacGrogan G., Bergh J., Cameron D., Goldstein D., Duss S., Nicoulaz A.L., Brisken C., Fiche M., Delorenzi M., Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671.
9. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
10. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
11. Hess A.R., Seftor E.A., Seftor R.E., Hendrix M.J. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. 2003, 63:4757-4762.
12. Hollier B.G., Tinnirello A.A., Werden S.J., Evans K.W., Taube J.H., Sarkar T.R., Sphyris N., Shariati M., Kumar S.V., Battula V.L., Herschkowitz J.I., Guerra R., Chang J.T., Miura N., Rosen J.M., Mani S.A. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast Cancer. Cancer Res. 2013, 73:1981-1992.
13. Irvin W.J., Carey L.A. What is triple-negative breast cancer?. Eur. J. Cancer 2008, 44:2799-2805.
14. Jechlinger M., Sommer A., Moriggl R., Seither P., Kraut N., Capodiecci P., Donovan M., Cordon-Cardo C., Beug H., Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest 2006, 116:1561-1570.
15. Kirschmann D.A., Seftor E.A., Hardy K.M., Seftor R.E., Hendrix M.J. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin. Cancer Res. 2012, 18:2726-2732.
16. Korpal M., Ell B.J., Buffa F.M., Ibrahim T., Blanco M.A., Celia-Terrassa T., Mercatali L., Khan Z., Goodarzi H., Hua Y., Wei Y., Hu G., Garcia B.A., Ragoussis J., Amadori D., Harris A.L., Kang Y. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17:1101-1108.
17. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest 2011, 121:2750-2767.
18. Liu T.J., Sun B.C., Zhao X.L., Zhao X.M., Sun T., Gu Q., Yao Z., Dong X.Y., Zhao N., Liu N. CD133(+) cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene 2012, 10.
19. Luqmani Y.A., Bansal G.S., Mortimer C., Buluwela L., Coombes R.C. Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast. Eur. J. Cancer 1996, 32A:518-524.
20. Ménard S. Heterogeneity of triple-negative breast carcinomas. Oncologie 2011, 14:28-30.
21. Moschetta M., Di P.G., Ria R., Gnoni A., Mangialardi G., Guarini A., Ditonno P., Musto P., D'Auria F., Ricciardi M.R., Dammacco F., Ribatti D., Vacca A. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur. J. Cancer 2010, 46:420-429.
22. Nissen L.J., Cao R., Hedlund E.M., Wang Z., Zhao X., Wetterskog D., Funa K., Brakenhielm E., Cao Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest 2007, 117:2766-2777.
23. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15:220-231.
24. Perou C.M. Molecular stratification of triple-negative breast cancers. The Oncologist 2011, 16(Suppl. 1):61-70.
25. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
26. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2011, 5:5-23.
27. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., Maira G., Parati E.A., Stassi G., Larocca L.M., De M.R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
28. Roland C.L., Dineen S.P., Lynn K.D., Sullivan L.A., Dellinger M.T., Sadegh L., Sullivan J.P., Shames D.S., Brekken R.A. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol. Cancer Ther. 2009, 8:1761-1771.
29. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer I 1990, 82:1107-1112.
30. Weigel M.T., Meinhold-Heerlein I., Bauerschlag D.O., Schem C., Bauer M., Jonat W., Maass N., Mundhenke C. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett. 2009, 273:70-79.
31. World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects. JAMA 2013, 310:2191-2194.